PENTA guidelines for the use of antiretroviral therapy, 2004

HIV Medicine

Volumn 5, Issue SUPPL. 2, 2004, Pages 61-86

  Sharland, Mike ^a   Blanche, S ^b   Castelli, G ^b   Ramos, J ^b   Gibb, D M ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; STEROID; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ACCURACY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE; AMNESIA; ANEMIA; ANOREXIA; ANTIBIOTIC RESISTANCE; ARTHRALGIA; BACTERIAL PNEUMONIA; BLISTER; BONE MARROW DISEASE; CHILD; CHILD CARE; CHILL; CLINICAL TRIAL; CONFUSION; CONJUNCTIVITIS; DEATH; DEPERSONALIZATION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DISEASE MARKER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DIZZINESS; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG USE; DYSPNEA; ECCHYMOSIS; EMOTIONAL DISORDER; ERYTHEMA; ESOPHAGUS ULCER; EUROPE; EVIDENCE BASED MEDICINE; FACE EDEMA; FATIGUE; FEVER; FLATULENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GENE MUTATION; GLOMERULONEPHRITIS; GLUCOSURIA; GOOD CLINICAL PRACTICE; GRANULOCYTOPENIA; GUILLAIN BARRE SYNDROME; HALLUCINATION; HEADACHE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEPATITIS; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPERPIGMENTATION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNE COMPLEX DISEASE; INJECTION PAIN; INJECTION SITE; INJECTION SITE REACTION; INTERPERSONAL COMMUNICATION; KETOACIDOSIS; KIDNEY DISEASE; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIVER DISEASE; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MALAISE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MENTAL DISEASE; MOUTH ULCER; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NONHUMAN; OSTEOMALACIA; OSTEOPOROSIS; PANCREAS DISEASE; PANCREATITIS; PARESTHESIA; PATIENT COMPLIANCE; PERINATAL DRUG EXPOSURE; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RESPIRATORY DISTRESS; RESTLESSNESS; REVIEW; RIGOR; RISK ASSESSMENT; SIDE EFFECT; SKIN CYST; SKIN INDURATION; SKIN NODULE; SOMNOLENCE; STEATOSIS; STEVENS JOHNSON SYNDROME; SYMPTOM; TASTE DISORDER; TERATOGENICITY; THOUGHT DISORDER; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE; UNPLEASANT DREAM; VIRUS LOAD; VOMITING;

ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, VERTICAL; EUROPE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; PATIENT SELECTION; RISK ASSESSMENT;

EID: 4043162723     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00227.x     Document Type: Review

References (78)

1. Paediatric European Network for Treatment of AIDS (PENTA). Five year follow up of vertically infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch Dis Child 2001; 84: 230-236.
2. Palumbo PE, Raskino C, Fiscus S et al. Disease progression in HIV infected infants and children: predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count. JAMA 1998; 279: 756-761.
3. Mofenson LM, Korelitz J, Meyer WA et al. The relationship between human immunodeficiency type 1 RNA level, CD4 lymphocyte percent, and mortality risk in HIV-1 infected children. J Infect Dis 1997; 175: 1029-1038.
4. Dunn D. HIV Pediatric Prognostic Markers Collaborative Study Group. Short term risk of disease progression in HIV-1 infected children receiving no antiretroviral therapy or zidovudine monotherapy; a meta-analysis. Lancet 2003; 362: 1605-1611.
5. Gibb DM, Duong T, Tookey PA et al. Decline in mortality AIDS and hospital admissions in perinatally HIV-1 infected children in the UK and Ireland. BMJ 2003; 327: 1019-1021.
6. Faye A. Mortality and morbidity in HIV-infected infants treated before 6 months of age. II Conference of International AIDS Society, Paris, 2003 [Abstract 33].
7. Ramos JT, Manso B, Otero MC et al. Early HAART in infants: a multicenter Spanish audit. 9th European AIDS Conference (EACS), Warsaw, 2003 [Abstract 15.2/2].
8. Faye A, Bertone C, Teglas JP et al. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J 2002; 21: 518-525.
9. Pediatric European Network for treatment of AIDS. A 72 week follow-up of HAART started in infants aged less than 3 months: CD4, viral load and drug resistance in the PENTA7 study. AIDS 2004; 18: 237-245.
10. Luzuriaga K, McManus M, Catalina M et al. Early therapy of vertical human immunodeficiency virus type-1 (HIV-1) , infection: control of viral replication and absence of persistent HIV-1 specific immune responses. J Virol 2000; 74: 6984-6991.
11. Sharland M, Gibb DM, Holland F. Respiratory morbidity from lymphocytic interstitial pneumonitis (LIP) in vertically acquired HIV infection. Arch Dis Child 1997; 76: 334-336.
12. Egger M, May M, Chene G et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 19-129.
13. Phillips AN, Lepin AC, Lampra F et al. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 2003; 17: 1863-1869.
14. ATCC - The Antiviral Therapy Cohort Collaboration. Prognostic importance of initial response in HIV-infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362: 679-686.
15. Litalien C, Faye A, Compagnucci A et al. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 2003; 22: 48-55.
16. Tudor-William G, Head S, Weigel R et al. Baby cocktail! A protease-sparing 4 drug combination for symptomatic children. XIV International AIDS Conference, Barcelona, 2002 [Abstract MoOrB1129].
17. Nachman SA, Stanley K, Yogev R et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy experienced HIV infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA 2000; 283: 492-498.
18. Wiznia A, Stanley K, Krogstad P et al. Combination nucleoside analog reverse transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral experienced HIV infected children: week 24 of a randomised controlled trial - PACTG 377. AIDS Res Human Retro 2000; 16: 1113-1121.
19. Gibb DM, Giaquinto C, Walker S et al. for the PENTA 5 Steering Committee. Three-year follow-up of the PENTA 5 Trial. 10th Conference of Retrovirus and Opportunistic Infections, Boston, 2003 [Abstract 874].
20. PENTA. Comparison of dual nucleoside analogue reverse-transcriptase inhibitor regimens with and without NFV in children with HIV who have not previously been treated: the PENTA 5 trial. Lancet 2002; 359: 733-740.
21. Gatell J. Nelfinavir 625 mg film-coated tablets. Investigation of safety and gastrointestinal tolerability of this new formulation in comparison with 250 mg film-coated tablets in HIV patients. 2nd International AIDS Society Conference, Paris, 2003 [Abstract 548].
22. Saez-Llorens X, Violari A, Deetz CO et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus infected children. Pediatr Infect Dis J 2003; 22: 216-223.
23. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341: 1865-1873.
24. Starr SE, Fletcher CV, Spector SA et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse transcriptase inhibitors in children infected with human immunodeficiency virus type 1. New Engl J Med 1999; 341: 1874-1881.
25. Robbins G, De Gruttola V, Shafer R et al. for the ACTG 384 Team. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. New Engl J Med 2003; 349: 2293-2303.
26. Verweel G, Sharland M, Lyall H et al. Nevirapine use in HIV-1 infected children. AIDS 2003; 17: 1639-1647.
27. Teglas J-P, Quartier P, Treluyer J-M et al. Tolerance of efavirenz in children. AIDS 2001; 15: 241-243.
28. Vibhagool A on behalf of the CNA3014 International Study Team. Ziagen (abacavir)/combivir versus indinavir/combivir in therapy naive adults. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001.
29. De Turchis P, Force G, Welker Y et al. Efficacy and safety of a quadruple combination combivir + abacavir + efavirenz regimen in antiretrovial treatment naive HIV-1 infected adults: La ranciliene. J Acquir Immune Defic Syndr 2002; 31: 178-182.
30. Wells CJ, Sharland M, Smith CJ. Triple nucleoside analogue therapy with zidovudine (AZT) lamivudine (3TC) and abacavir (ABC) in the paediatric HIV in South London (PHILS-NET) cohort. A 72 week update. World Aids Conference, Bangok, 2004 [Abstract 2038].
31. Bergshoeff A, Burger D, Farrelly L et al. Pharmacokinetics of once daily vs. twice daily lamivudine and abacavir in HIV-1 infected children: PENTA 13. 11th Conference on Retroviruses and Opportunistic Infections, S. Francisco, 2004 [Abstract 934].
32. Wang LH, Wiznia AA, Rathore MH et al. Pharmacokinetics and safety of single oral doses emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004; 48: 183-190.
33. Hazra R, Balis FM, Tullio AN et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004; 48: 124-129.
34. Hazra R, Gafnis R, Maldarelli F et al. Safety, tolerability and clinical responses to tenofovir DF in combination with other antiretrovirals in heavily treatment-experienced HIV-infected children: data through 48 weeks. 11th Conference on Retroviruses and Opportunistic Infections, S. Francisco, 2004 [Abstract 928].
35. McKinney R, Rathore M, Jankelovich S et al. PACTG 1021: an ongoing phase I/II study of once-daily emtricabine, didanosine, and efavirenz in therapy-naive or minimally treated pediatric patients. 10° Conference of Retrovirus and Opportunistic Infections, Boston, 2003 [Abstract 873].
36. Saez-Llorens X, Violari A, Ndiweni D et al. for FTC-203 Study Team. Once-daily emtricitabine in HIV-infected pediatric patients with other antiretroviral agents. 10th Conference of Retrovirus and Opportunistic Infection, Boston, 2003 [Abstract 872].
37. Williams I, Asboe D, Babiker A et al. A virological benefit from an induction/maintenance strategy: The FORTE Trial. 11th Conference on Retroviruses and Opportunistic Infections, Chicago, 2004 [Abstract 564].
38. McComsey G, Nasreen B, Jen-Fu M, Rathore M, Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the first pediatric switch study. Pediatrics 2003; 3: 275-281.
39. Gibb DM. Duong T. Leclezio VA et al. Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2000; 63: 446-450.
40. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 2003; 63: 741-753.
41. Lawrence J, Mayers DL, Hullsiek KH et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349: 837-846.
42. Starr SE, McFarland EJ, Muresan P et al. Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children. AIDS 2003; 17: 2181-2189.
43. Van Dyke RB, Lee S, Johnson GM et al. Reported adherence as a determinant of response to HAART in children who have HIV infection. Pediatrics 2002; 109: e61.
44. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13: 1763-1769.
45. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
46. Farley J, Hines S. Musk A. Ferrus S. Tapper V. Assessment of adherence to antiviral therapy in HIV-infected children using the medication Event monitoring system, pharmacy refill, provider assessment, Caregiver self-report, and appointment keeping. J Acquir Immune Defic Syndr 2003; 33: 211-218.
47. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999; 18: 682-689.
48. Reddington C, Cohen J, Baldillo A et al. Adherence to medication regimens among human immunodeficiency virus infection. Pediatr Infect Dis J 2000; 19: 1148-1153.
49. Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H for the PENTA Steering Committee. Adherence to prescribed antiretroviral therapy in with human immunodeficiency virus infected children. Pediatr Infect Dis J 2003; 22: 56-62.
50. Katko ERN, Johnson G, Fowler S, Ronald T. Assessment of adherence in human immunodeficiency virus infected children. Pediatr Infect Dis J 2001; 20: 1174-1176.
51. Temple ME, Koranyi KI, Nahata MC. Gastrostomy tube placement in nonadherent HIV-infected children. Ann Pharmacother 2001; 35: 414-418.
52. Melvin AJ, Lewis PF, Mohan KM, Naugler WS, Frenkel LM. Efficacy and toxicity of antiretroviral therapy using 4 or more agents: application of a strategy for antiretroviral management in human immunodeficiency virus-infected children. Arch Pediatr Adolesc Med 2002; 156: 568-573.
53. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003; 22: 77-84.
54. Amaya RA, Koezinetz CA, McMeaans A, Schwardwald H, Kline MA. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21: 405-410.
55. Ramos JT, García L, Rojo P et al. High prevalence of metabolic abnormalities in HIV-infected children treated with HAART. 10th Conference on Retrovirus and Opportunistic Infections, Boston, 2003 [Abstract 772].
56. Jaquet D, Lévine M, Ortega-Rodríguez E et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000; 14: 2123-2128.
57. Vigano A, Thorne C. Fat redistribution and metabolic abnormalities in HIV-infected children and adolescents in Europe. 10th Conference on Retrovirus and Opportunistic Infections, Boston, 2003 [Abstract 774].
58. Arpadi S, Cuff P, Horlick M, Wang J, Kotler DP. Lypodystrophy in HIV-infected children is associated with high viral load and low CD4-lymphocyte count and CD4-lymphocyte percentage and baseline and use of protease inhibitors and stavudine. J Acquir Immun Def Syndr 2001; 27: 30-34.
59. Brambilla P, Bricalli D, Sala N et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001; 15: 2415-2422.
60. Watson DC, Farley JJ. Hypercholesterolemia in children treated with HIV protease inhibitors. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 [Abstract 435].
61. Cheseaux JJ, Jotterand V, Aebi C et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr J 2002; 30: 288-293.
62. Schambelan M, Benson CA, Carr A et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr 2002; 31: 257-275.
63. Brinkman K. Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis 2000; 31: 167-169.
64. Noguera A, Fortuny C, Sanchez E et al. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatr Infect Dis J 2003; 22: 778-782.
65. Church JA, Mitchell WG, Gonzalez-Gomez I et al. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr 2001; 138: 748-751.
66. Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22: 782-789.
67. Blanche S, Tardieu M, Rustin P et al. Persistent mitochondrial dysfunction and perinatal exposure to antirtroviral nucleoside analogues. Lancet 1999; 354: 1084-1089.
68. Barret B, Tardieu M, Rustin P et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17: 1769-1785.
69. Miller K, Masur H, Jones EC et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137: 17-24.
70. Gaughan DM, Mofenson LM, Hughes MD, Seage S, Oleske J for the PACTG 219 Team. Avascular necrosis of the hip (Leggs-Calve-Perthes disease) in HIV-infected children in long-term follow-up: PACTG Study 219. Pediatrics 2002; 109: e74, 1-8.
71. Tebas P, Powderky WG, Claxton S et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14: F63-F67.
72. Thomas J, Doherty SM. HIV infection - a risk factor for osteoporosis. J Acquir Immune Def Syndr 2003; 33: 281-291.
73. Arpadi S, Horlick M, Thornton J, Cuff PA, Wang J, Kotler DP. Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Def Syndr 2002; 29: 450-454.
74. Vigano A, Zamproni I, Giacomet V, Bianchi R, Figini C, Mora S. Analysis of bone mineral content in antiretroviral-naive and highly active antiretroviral treated HIV-infected children. 11th Conference on Retrovirus and Opportunistic Infections, S. Francisco, 2004 [Abstract 943].
75. Schwarzwald H, Ellis KJ, Evans DL et al. Effect of HAART on bone density in HIV-infected children. 10th Conference on Retrovirus and Opportunistic Infections, Boston, 2003 [Abstract 778].
76. Oleske JM, Gaughan DM, Mofenson LM, Seage GR, Dankner VM, Hughes MD. Bone disorders in HIV-infected and -exposed children. 14th World AIDS Conference, Barcelona, 2002 [Abstract TuPpB 2053].
77. Mondy K, Powderly WG, Claxto SA et al. Alendronate, vitamin D and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. 10th Conference on Retrovirus and Opportunistic Infections, Boston, 2003 [Abstract 134].
78. Justman JE, Benniing L, Danoff A et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 298-302.